Vir Biotechnology, Inc. Form 8-K (July 11, 2022)

Summary

Form 8-K current report of Vir Biotechnology, Inc. dated July 11, 2022, filed under Item 5.02. It reports that on July 11, 2022 Herbert (Skip) Virgin, M.D., Ph.D., notified the company that he will step down as Executive Vice President, Research and Chief Scientific Officer, effective August 31, 2022. The report is dated July 14, 2022 and signed by Howard Horn.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 11, 2022

Vir Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-39083 | 81-2730369
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
499 Illinois Street , Suite 500 San Francisco , California | 94158
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code: (415) 906-4324

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.0001 par value | VIR | Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 11, 2022, Herbert (Skip) Virgin, M.D., Ph.D., notified Vir Biotechnology, Inc. (the “Company”) that he will step down as Executive Vice President, Research and Chief Scientific Officer of the Company effective August 31, 2022.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VIR BIOTECHNOLOGY, INC.
Date: July 14, 2022 | By: | /s/ Howard Horn
Howard Horn
Executive Vice President, Chief Financial Officer and Secretary

File and source

File

SEC_VIR_8-K_filed2022-07-14_0001193125-22-193370.htm

Size

22,586 bytes

SHA-256

0fd036d722ecb9a4dd967de62bb96bf02d4c2eb79a9a688358a602c3314b8535

Our copy

SEC_VIR_8-K_filed2022-07-14_0001193125-22-193370.htm

Original

www.sec.gov